<DOC>
	<DOCNO>NCT00721916</DOCNO>
	<brief_summary>This randomize , multicenter study design evaluate progression free survival SOL group ( S-1 , Leucovorin , Oxaliplatin ) compare mFOLFOX6 group ( 5-FU , l-LV Oxaliplatin ) first-line treatment patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Randomized Phase II Study SOL Untreated Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically prove adenocarcinoma ( colorectal cancer ) . Age : 20 â‰¤ enrollment . No prior treatment ( ex . radiation therapy , chemotherapy , hormonal therapy ) advance disease . Patients receive adjuvant chemotherapy 180 day enrollment allow receive S1 Oxaliplatin contain treatment shall exclude . At least one measurable lesion RECIST criterion Serious drug hypersensitivity . Prior history peripheral neuropathy . Diarrhea . Simultaneously active double cancer .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>